Let's look at why this news could be a game-changer for Eli Lilly and its stock.

2024 saw the first FDA approval of a cancer cell therapy that tackles solid tumours ... pre-registration phase waiting for a regulatory decision. Of these, 20% were GLP-1 drugs alone, with ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

the side effects of popular weight loss drugs and how to safely transition off them while maintaining long-term success. Weight loss medications like Wegovy and Zepbound offer powerful tools in ...

Propensity score matching minimized demographic and disease prevalence differences, though the GLP-1 RA group still had higher HbA1c and BMI, reflecting greater disease severity at drug initiation.

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.